Investigations into Viomycin Biosynthesis by Using Heterologous Production in Streptomyces lividans
- 15 January 2009
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 10 (2) , 366-376
Abstract
Viomycin and capreomycin are members of the tuberactinomycin family of antituberculosis drugs. As with many antibacterial drugs, resistance to the tuberactinomycins is problematic in treating tuberculosis; this makes the development of new derivatives of these antibiotics to combat this resistance of utmost importance. To take steps towards developing new derivatives of this family of antibiotics, we have focused our efforts on understanding how these antibiotics are biosynthesized by the producing bacteria so that metabolic engineering of these pathways can be used to generate desired derivatives. Here we present the heterologous production of viomycin in Streptomyces lividans 1326 and the use of targeted‐gene deletion as a mechanism for investigating viomycin biosynthesis as well as the generation of viomycin derivatives. Deletion of vioQ resulted in nonhydroxylated derivatives of viomycin, while strains lacking vioP failed to acylate the cyclic pentapeptide core of viomycin with β‐lysine. Surprisingly, strains lacking vioL produced derivatives that had the carbamoyl group of viomycin replaced by an acetyl group. Additionally, the acetylated viomycin derivatives were produced at very low levels. These two observations suggested that the carbamoyl group of the cyclic pentapeptide core of viomycin was introduced at an earlier step in the biosynthetic pathway than previously proposed. We present biochemical evidence that the carbamoyl group is added to the β‐amino group of L‐2,3‐diaminopropionate prior to incorporation of this amino acid by the nonribosomal peptide synthetases that form the cyclic pentapeptide cores of both viomycin and capreomycin.Keywords
This publication has 33 references indexed in Scilit:
- Multidrug‐Resistant and Extensively Drug‐Resistant Tuberculosis: The National Institute of Allergy and Infectious Diseases Research Agenda and Recommendations for Priority ResearchThe Journal of Infectious Diseases, 2008
- Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis casesEuropean Respiratory Journal, 2008
- Identification of the Biosynthetic Gene Cluster and an Additional Gene for Resistance to the Antituberculosis Drug CapreomycinApplied and Environmental Microbiology, 2007
- Surprising Arginine Biosynthesis: a Reappraisal of the Enzymology and Evolution of the Pathway in MicroorganismsMicrobiology and Molecular Biology Reviews, 2007
- Roles of VioG and VioQ in the Incorporation and Modification of the Capreomycidine Residue in the Peptide Antibiotic ViomycinJournal of Natural Products, 2007
- Rieske business: Structure–function of Rieske non-heme oxygenasesBiochemical and Biophysical Research Communications, 2005
- Nucleotide binding by multienzyme peptide synthetasesEuropean Journal of Biochemistry, 1994
- A Broad Host Range Mobilization System for In Vivo Genetic Engineering: Transposon Mutagenesis in Gram Negative BacteriaBio/Technology, 1983
- Resistance to viomycin conferred by RNA of either ribosomal subunitNature, 1978
- A complementation analysis of the restriction and modification of DNA in Escherichia coliJournal of Molecular Biology, 1969